Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that two of its topical drugs produced significant inhibitory effects in a well-established mouse model of atopic dermatitis (AD). AD is a chronic inflammatory skin disease with significant unmet need that is often linked to depression and a decreased quality of life. Recently published research reports estimate the global AD treatment market to reach as high as USD $34 billion by 2026.
Dr. Youwen Zhou, Professor of Dermatology at the University of British Columbia, and Director of Skin Research Program, Vancouver Coastal Health Research Institute: “Atopic dermatitis is an intensely itchy inflammatory skin disease that causes physical and psychological suffering in millions of people worldwide. The currently available therapies, including the most recent FDA-approved drug, crisaborole, are unsatisfactory due to limitations in effectiveness or tolerability. Therefore, it is exciting to discover that several of Derm-Biome’s newly developed compounds far outperformed crisaborole in blocking the development of skin inflammation in a mouse model of atopic dermatitis. If confirmed in further experimental testing, these compounds hold strong potential to become the next generation of therapies for the treatment of atopic dermatitis”.
